Symbicort (budesonide/formoterol) Turbuhaler + Conventional treatment

Phase 3Terminated
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Asthma, Bronchial

Conditions

Asthma, Bronchial

Trial Timeline

Sep 1, 2006 โ†’ Oct 1, 2008

About Symbicort (budesonide/formoterol) Turbuhaler + Conventional treatment

Symbicort (budesonide/formoterol) Turbuhaler + Conventional treatment is a phase 3 stage product being developed by AstraZeneca for Asthma, Bronchial. The current trial status is terminated. This product is registered under clinical trial identifier NCT00385593. Target conditions include Asthma, Bronchial.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00385593Phase 3Terminated